New England Research & Management Inc. Buys New Stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

New England Research & Management Inc. bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor bought 5,050 shares of the specialty pharmaceutical company's stock, valued at approximately $627,000.

Several other large investors have also made changes to their positions in the business. IFP Advisors Inc purchased a new stake in Jazz Pharmaceuticals in the 4th quarter worth $25,000. Quadrant Capital Group LLC lifted its holdings in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after purchasing an additional 101 shares in the last quarter. Elequin Capital LP grew its position in shares of Jazz Pharmaceuticals by 677.8% in the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after purchasing an additional 183 shares during the period. CoreFirst Bank & Trust purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $28,000. Finally, Allianz SE purchased a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $29,000. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $123.75, for a total transaction of $185,625.00. Following the completion of the transaction, the chief executive officer now directly owns 440,307 shares in the company, valued at approximately $54,487,991.25. This represents a 0.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Seamus Mulligan acquired 100,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 9th. The stock was bought at an average price of $98.26 per share, for a total transaction of $9,826,000.00. Following the completion of the acquisition, the director now owns 100,000 shares in the company, valued at $9,826,000. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have sold 3,000 shares of company stock valued at $355,925. 4.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on JAZZ shares. Royal Bank Of Canada decreased their price target on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Robert W. Baird reduced their target price on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a report on Wednesday, May 7th. HC Wainwright lifted their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. JPMorgan Chase & Co. boosted their price target on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC restated a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $184.00.

Jazz Pharmaceuticals Trading Down 2.4%

Shares of NASDAQ JAZZ traded down $2.59 during trading on Tuesday, hitting $107.05. 539,572 shares of the company were exchanged, compared to its average volume of 832,594. The company has a fifty day moving average price of $107.91 and a 200-day moving average price of $120.35. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.97 and a current ratio of 3.38. The firm has a market capitalization of $6.48 billion, a PE ratio of 14.27, a P/E/G ratio of 4.73 and a beta of 0.33. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 EPS for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. Jazz Pharmaceuticals's revenue for the quarter was down .5% on a year-over-year basis. During the same period last year, the firm earned $2.68 earnings per share. As a group, equities research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.